Related Experiment Videos
Beta-blocker therapy in heart failure in the elderly.
1Heart Failure Center Medicine, Sahlgrenska University Hospital/Sahlgrenska, 413 45 Göteborg, Sweden. Michael.fu@vgregion.se
International Journal of Cardiology
|November 21, 2007
Summary
Beta-blockers are beneficial for elderly heart failure patients, but evidence is limited. Further research is needed to confirm optimal dosing and benefits in this population.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Chronic heart failure (CHF) significantly impacts the elderly, with increasing morbidity and mortality.
- Beta-blocker therapy is supported by some evidence in elderly CHF patients, yet its use remains lower than in younger populations.
- Uncertainty exists regarding the efficacy and tolerability of beta-blockers in older adults compared to younger individuals.
Purpose of the Study:
- To review the current evidence for beta-blocker use in elderly patients with chronic heart failure.
- To address the uncertainties surrounding the benefit-risk profile and optimal dosing of beta-blockers in seniors.
- To highlight the need for further research to guide evidence-based management of heart failure in the elderly.
Main Methods:
- Review of existing literature, including landmark trials like the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS).
- Analysis of retrospective subgroup data from clinical trials in stable systolic heart failure.
- Discussion of clinical experience and theoretical considerations regarding beta-blocker dosing in the elderly.
Main Results:
- While generally well-tolerated, achieving target beta-blocker doses can be challenging in elderly patients.
- Existing data, though supportive, is not as robust as for younger CHF populations.
- The SENIORS trial and subgroup analyses provide some evidence for beta-blocker efficacy in seniors.
Conclusions:
- Beta-blockers are a cornerstone of heart failure management, even in the elderly, but require further investigation.
- Active research is crucial to establish clear outcome improvements and benefit-risk analyses for beta-blockers in older adults, considering comorbidities and polypharmacy.
- Until more definitive data is available, current beta-blocker therapy, which is relatively well-documented, should be continued for elderly heart failure patients.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...